Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Rituximab Activates NOTCH1 Signaling in CLL Cells and Induces Changes in the Cytokine Repertoire Favoring a Tumor-Protective Microenvironment

Jennifer Edelmann, MD PhD, Karlheinz Holzmann, Dr. rer. nat., Doriana DiBella, Emma Vilventhraraja, Stephen A Beers, PhD, Mark Cragg, PhD, Andrejs Braun, PhD, John G. Gribben, MDDSc FMedSci

Blood (2017) 130 (Supplement 1): 2996.

https://doi.org/10.1182/blood.V130.Suppl_1.2996.2996

Published: 2017

Journal Articles

In Chronic Lymphocytic Leukemia ΔCT7544-7545 Mutant NOTCH1 Maintains Transcription Factor Activity with Longer Lasting Effects Due to Slower Degradation

Jennifer Edelmann, MD, Tetyana Klymenko, PhD, Chen Lu, PhD, Emma Vilventhraraja, Sven Estenfelder, Eugen Tausch, Stephen A Beers, PhD, Stephan Stilgenbauer, Mark S Cragg, PhD, Andrejs Ivanov, PhD, John Gribben

Blood (2016) 128 (22): 971.

https://doi.org/10.1182/blood.V128.22.971.971

Published: 2016

Journal Articles

Anti-CD27 Enhances Lymphoma Immunotherapy through Profound Myeloid Cell Recruitment

Anna H Turaj, MSc, Vikki L Field, Claude H.T. Chan, PhD, Christine A. Penfold, BSc, Jinny H. Kim, PhD, Sonya James, PhD, Kerry L Cox, Tibor Keler, PhD, Peter M Johnson, MA, MD, Aymen Al-Shamkhani, PhD, Stephen A Beers, PhD, Martin J. Glennie, PhD, Mark S Cragg, PhD, Sean H Lim, MD PhD

Blood (2016) 128 (22): 3024.

https://doi.org/10.1182/blood.V128.22.3024.3024

Published: 2016

Journal Articles

Influence of immunoglobulin isotype on therapeutic antibody function

Stephen A. Beers, Martin J. Glennie, Ann L. White

Blood (2016) 127 (9): 1097–1101.

https://doi.org/10.1182/blood-2015-09-625343

Published: 2016

Journal Articles

Anti-mouse FcγRIV antibody 9E9 also blocks FcγRIII in vivo

Thomas R. W. Tipton, C. Ian Mockridge, Ruth R. French, Alison L. Tutt, Mark S. Cragg, Stephen A. Beers

Blood (2015) 126 (24): 2643–2645.

https://doi.org/10.1182/blood-2015-09-671339

Published: 2015

Includes: Supplemental data

Journal Articles

Defining Immune Response Signatures in DLBCL As Potential Predictive Biomarkers for Outcome to Immunotherapy

Matthew A Care, PhD, Stephen M Thirdborough, PhD, Andrew J Davies, MRCP PhD, Peter W.M. Johnson, FRCP, Andrew Jack, PhD MB, Sharon Barrans, PhD, David R Westhead, PhD, Mark S Cragg, PhD, Reuben M Tooze, PhD FRCP, Stephen A Beers, PhD

Blood (2015) 126 (23): 2663.

https://doi.org/10.1182/blood.V126.23.2663.2663

Published: 2015

Journal Articles

Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies

Thomas R. W. Tipton, Ali Roghanian, Robert J. Oldham, Matthew J. Carter, Kerry L. Cox, C. Ian Mockridge, Ruth R. French, Lekh N. Dahal, Patrick J. Duriez, Philip G. Hargreaves, Mark S. Cragg, Stephen A. Beers

Blood (2015) 125 (12): 1901–1909.

https://doi.org/10.1182/blood-2014-07-588376

Published: 2015

Includes: Supplemental data

Journal Articles

Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity

Andrew T. Vaughan, Chisako Iriyama, Stephen A. Beers, Claude H. T. Chan, Sean H. Lim, Emily L. Williams, Vallari Shah, Ali Roghanian, Bjorn Frendéus, Martin J. Glennie, Mark S. Cragg

Blood (2014) 123 (5): 669–677.

https://doi.org/10.1182/blood-2013-04-490821

Published: 2014

Includes: Supplemental data

Journal Articles

Neutrophils: “neu players” in antibody therapy?

Stephen A. Beers, Martin J. Glennie

Blood (2013) 122 (18): 3093–3094.

https://doi.org/10.1182/blood-2013-09-525451

Published: 2013

Journal Articles

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy

Sean H. Lim, Andrew T. Vaughan, Margaret Ashton-Key, Emily L. Williams, Sandra V. Dixon, H. T. Claude Chan, Stephen A. Beers, Ruth R. French, Kerry L. Cox, Andrew J. Davies, Kathleen N. Potter, C. Ian Mockridge, David G. Oscier, Peter W. M. Johnson, Mark S. Cragg, Martin J. Glennie

Blood (2011) 118 (9): 2530–2540.

https://doi.org/10.1182/blood-2011-01-330357

Published: 2011

Includes: Supplemental data

Journal Articles

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

Waleed Alduaij, Andrei Ivanov, Jamie Honeychurch, Eleanor J. Cheadle, Sandeep Potluri, Sean H. Lim, Kazuyuki Shimada, Claude H. T. Chan, Alison Tutt, Stephen A. Beers, Martin J. Glennie, Mark S. Cragg, Tim M. Illidge

Blood (2011) 117 (17): 4519–4529.

https://doi.org/10.1182/blood-2010-07-296913

Published: 2011

Includes: Multimedia, Supplemental data

Journal Articles

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

Stephen A. Beers, Ruth R. French, H. T. Claude Chan, Sean H. Lim, Timothy C. Jarrett, Regina Mora Vidal, Sahan S. Wijayaweera, Sandra V. Dixon, Hyungjin Kim, Kerry L. Cox, Jonathan P. Kerr, David A. Johnston, Peter W. M. Johnson, J. Sjef Verbeek, Martin J. Glennie, Mark S. Cragg

Blood (2010) 115 (25): 5191–5201.

https://doi.org/10.1182/blood-2010-01-263533

Published: 2010

Includes: Supplemental data

Journal Articles

Complement: help or hindrance?

Stephen A. Beers, Mark S. Cragg, Martin J. Glennie

Blood (2009) 114 (27): 5567–5568.

https://doi.org/10.1182/blood-2009-10-249466

Published: 2009

Journal Articles

New-Generation Anti-CD20 Monoclonal Antibody (GA101) Evokes Homotypic Adhesion and Actin-Dependent, Lysosome-Mediated Cell Death in B-Cell Lymphoma.

Waleed Alduaij, MRes, Sandeep Potluri, BA, Andrei Ivanov, PhD, Jamie Honeychurch, PhD, Stephen A Beers, PhD, Claude Chan, PhD, Kazayuki Shimada, MD, Martin J. Glennie, PhD, Mark S Cragg, PhD, Tim Illidge, MD, PhD

Blood (2009) 114 (22): 725.

https://doi.org/10.1182/blood.V114.22.725.725

Published: 2009

Journal Articles

Novel Mechanisms of Non-Apoptotic Cell Death Evoked by Type II Anti-CD20 (Tositumomab) and HLA-DR Monoclonal Antibodies

Tim Illidge, MD, PhD, Andrei Ivanov, PhD, Stephen A Beers, PhD, Claire Walshe, PhD, Claude Chan, PhD, Waleed Alduaij, Martin J. Glennie, PhD, Mark S Cragg

Blood (2008) 112 (11): 883.

https://doi.org/10.1182/blood.V112.11.883.883

Published: 2008

Journal Articles

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

Stephen A. Beers, Claude H. T. Chan, Sonya James, Ruth R. French, Kathrine E. Attfield, Claire M. Brennan, Anupama Ahuja, Mark J. Shlomchik, Mark S. Cragg, Martin J. Glennie

Blood (2008) 112 (10): 4170–4177.

https://doi.org/10.1182/blood-2008-04-149161

Published: 2008

Includes: Supplemental data

Journal Articles

Response: Superior B cell–depleting activity of type II anti-CD20 mAb is not due to activation of complement

Stephen A. Beers, Mark S. Cragg, Martin J. Glennie

Blood (2008) 112 (10): 4355–4356.

https://doi.org/10.1182/blood-2008-08-172999

Published: 2008

NARROW

Rituximab Activates NOTCH1 Signaling in CLL Cells and Induces Changes in the Cytokine Repertoire Favoring a Tumor-Protective Microenvironment

In Chronic Lymphocytic Leukemia ΔCT7544-7545 Mutant NOTCH1 Maintains Transcription Factor Activity with Longer Lasting Effects Due to Slower Degradation

Anti-CD27 Enhances Lymphoma Immunotherapy through Profound Myeloid Cell Recruitment

Influence of immunoglobulin isotype on therapeutic antibody function

Anti-mouse FcγRIV antibody 9E9 also blocks FcγRIII in vivo

Defining Immune Response Signatures in DLBCL As Potential Predictive Biomarkers for Outcome to Immunotherapy

Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies

Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity

Neutrophils: “neu players” in antibody therapy?

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

Complement: help or hindrance?

New-Generation Anti-CD20 Monoclonal Antibody (GA101) Evokes Homotypic Adhesion and Actin-Dependent, Lysosome-Mediated Cell Death in B-Cell Lymphoma.

Novel Mechanisms of Non-Apoptotic Cell Death Evoked by Type II Anti-CD20 (Tositumomab) and HLA-DR Monoclonal Antibodies

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

Response: Superior B cell–depleting activity of type II anti-CD20 mAb is not due to activation of complement

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only